Evaluation of the Expression Level and Hormone Receptor Association of miR-126 in Breast Cancer

Rouigari, Maedeh; Dehbashi, Moein; Tabatabaeian, Hossein; Ghaedi, Kamran; Mohammadynejad, Parisa; Azadeh, Mansoureh

doi:10.1007/s12291-018-0766-6

Cited by 14 publications

(7 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Particularly, miR-200c downregulation has been found in both TNBC tissues and BC cells, and therefore, it could be used as a valuable marker for BC progression and prognosis . It has been reported that miR-126 expression levels are lower in ER+ BC and ductal carcinoma in situ breast tissues as compared to normal adjacent ones, and this downregulation is correlated with shorter overall survival. − Loss of miR-126 expression in BC tissue has also been related to poor distal metastasis-free survival, while restoration of miR-126 suppresses overall tumor growth and proliferation …”

Section: Introductionmentioning

confidence: 99%

BRCA Mutations and MicroRNA Expression Patterns in the Peripheral Blood of Breast Cancer Patients

Alavanda,

Dirimtekin,

Mortoglou

et al. 2024

ACS Omega

View full text Add to dashboard Cite

Breast cancer (BC) persists as the predominant malignancy globally, standing as the foremost cause of cancer-related mortality among women. Despite notable advancements in prevention and treatment, encompassing the incorporation of targeted immunotherapies, a continued imperative exists for the development of innovative methodologies. These methodologies would facilitate the identification of women at heightened risk, enhance the optimization of therapeutic approaches, and enable the vigilant monitoring of emergent treatment resistance. Circulating microRNAs (miRNAs), found either freely circulating in the bloodstream or encapsulated within extracellular vesicles, have exhibited substantial promise for diverse clinical applications. These applications range from diagnostic and prognostic assessments to predictive purposes. This study aimed to explore the potential associations between BRCA mutations and specific miRNAs (miR-21, miR-155, miR-126, and miR-200c) expression that are known to be dysregulated in BC patient samples. Our findings indicate a robust correlation between miRNA expression status and disease subtypes. We found a correlation between the expression status of miRNAs and distinct disease subtypes. Intriguingly, however, no significant associations were discerned between disease status, subtypes, or miRNA expression levels and the presence of BRCA mutations. To advance the validation of miRNAs as clinically relevant biomarkers, additional investigations within larger and meticulously selected patient cohorts are deemed imperative. These microRNA entities hold the potential to emerge as groundbreaking and readily accessible tools, poised for seamless integration into the landscape of clinical practice.

show abstract

Section: Introductionmentioning

confidence: 99%

BRCA Mutations and MicroRNA Expression Patterns in the Peripheral Blood of Breast Cancer Patients

Alavanda,

Dirimtekin,

Mortoglou

et al. 2024

ACS Omega

View full text Add to dashboard Cite

show abstract

“…Breast cancer accounts for 30% of all cancers in women (7). Breast cancer (BC) is a kind of neoplasia that affects predominantly women (8,9) and a major reason of cancer-related death among women (10). According to the previous studies, NME1 can control the invasive switch of BC during the regulating MT1-MMP surface clearance.…”

Section: Introductionmentioning

confidence: 99%

The dysregulation of NME1, LINC00511, and LINC01028 could disturb the regular apoptosis process and promote breast cancer in the Isfahan population: integrated bioinformatics and experimental analyses

Bakhshayesh

Chamgordani

Sanaei

et al. 2022

Preprint

Self Cite

View full text Add to dashboard Cite

Background: NME1 is a crucial gene in the proliferation, cancer survival, and differentiation processes. The abnormal changes in the expression of NME1 could cause disturbance in the mentioned processes and lead the normal cells to different abnormalities, including cancer. Breast cancer is the most frequently diagnosed cancer in women and ranks second among causes for cancer related death in women. In this study, the expression pattern of NME1 and the two lncRNAs that have possible interaction with NME1 (LINC01028 and LINC00528) had been evaluated In the Isfahan breast cancer (BC) patients.Methods and results: Microarray, pathway enrichment, Gene Ontology, RNA and Protein interaction, and co-expression analyses were performed to find novel integrated genes, proteins, and RNAs (coding and non-coding) in the BC patients, based on the bioinformatics tools (R programming language and online databases). After finding novel genes and RNAs, a real-time PCR experiment was performed to evaluate the accurate relative expression of found RNAs in the Isfahan human breast cancer samples. Bioinformatics analyses revealed that NME1 protein could regulate apoptotic-related proteins. Also, based on ENCORI and microarray data analysis, the expression of NME1 and LINC00511 (FC: 6.49, FDR < 0.0001) have a significant up-regulation in the BC samples. Also, LINC01028 had a significantly low expression in the mentioned datasets (FC: 0.08, FDR < 0.0001). A real-time PCR experiment validated the bioinformatics results. Based on the experiment, NME1 (logFC: 2.664, P. Value < 0.0001) and LINC00511 (logFC: 2.058, P. Value: 0.0180). Also, LINC01028 have significant low-expression in the BC samples (logFC: -2.219, P. Value: 0.0006).Conclusion: Based on the bioinformatics and experimental analyses, NME1, LINC00511, and LINC01028 could be three prognostic biomarkers in the Isfahan BC population. The disturbance of the expression level of mentioned RNAs can change the regular apoptosis process and promote BC development in the patients.

show abstract

“…More than 60% of BC deaths occur in developing countries (16). BC also is one of the main reasons of cancer-related death in woman worldwide (17)(18)(19). The development of mutations in the genome that result in the gain of function or activation of oncogenes like Human Epidermal Growth Factor Receptor 2 (HER2), mTOR, PI3K, EpCAM, PTBP1, HER4, and WBP2 or the loss of function or deactivation of tumor suppressor genes like p53, BRCA1/2, and p21 is what causes cancer (20).…”

Section: Introductionmentioning

confidence: 99%

ADAMTS5 modulates breast cancer development as a diagnostic biomarker and potential tumor suppressor, regulating by BAIAP2-AS1, VTI1B, CRNDE, and hsa-miR-135b-3p: integrated systems biology and experimental approach

Tavousi

Taqizadeh

Nasiriyan

et al. 2022

Preprint

Self Cite

View full text Add to dashboard Cite

Background: A disintegrin and metalloproteinases (ADAMs) are a novel gene family of proteins that share the metalloproteinase domain with matrix metalloproteinases and have sequence similarities to the reprolysin family of snake venomases (MMPs). They are divided into two classes based on their structural similarities: membrane-anchored ADAM and ADAM with thrombospondin motifs (ADAMTS). These molecules have a role in a number of biological processes, including membrane protein shedding, proteolysis, cell adhesion, cell fusion, and cell migration. Method: In this study, the RNA interaction analysis (miRWalk, lncRRisearch, ENCORI, and lncBase3) and protein interaction analysis (STRING) was performed. Survival, expression, and correlation analyses was performed by ENCORI and GEPIA2. Expression analysis also performed by microarray analysis. GSEA analysis was performed to find top up and down-regulated genes and relevant signaling pathway. Gene ontology analysis was performed by g: Profiler and clusterprofiler. Pathway enrichment was performed by GSEA analysis.ResultsADAMTS5 has a significant low-expression, based on ENCORI (Fold Change: 0.12, FDR < 0.0001), microarray analysis (logFC: -3.791881, adj. P. Val < 0.0001), and qRT-PCR experiment (logFC: -1.975, FC: 0.025, p. value < 0.0001, patients under 40). ADAMTS5 is a potential diagnostic biomarker of BC, based on ROC curve (AUC: 0.75, p. value: 0.0007). mRNA VTI1B, lncRNAs CRNDE and BAIAP2-AS1, and hsa-miR-135a-3b have interaction with ADAMTS5. VTI1B has a significant low-expression (FC: 0.65, FDR: 0.0001). BAIAP2-AS1 is significantly up-regulated (FC: 1.37, FDR: 0.0001). CRNDE is significantly up-regulated (FC: 1.30, FDR: 0.0001). BAIAP2 (log-Rank p: 0.0017, Hazard Ratio: 0.59) and CRNDE (log-Rank p: 0.34, Hazard Ratio: 1.17) are the two potential BC survival predictor.ConclusionIn this study, we performed a differential expression analysis on the expression level of ADAMTS5, VTI1B, and BAIAP2-AS1 in the BC patients for the first time. ADAMTS5 and its correlated oncogene and tumor suppressor RNAs and proteins are the hub therapeutic target of BC. DEGs of the GSE42568 dataset are involve in PPAR and cell cycle checkpoint signaling pathways and during the regulation of mentioned pathway, regulate the BC development. Targeting the expression and interaction of mentioned RNAs can be helpful for the diagnosis, prognosis, and treatment of BC.

show abstract

Evaluation of the Expression Level and Hormone Receptor Association of miR-126 in Breast Cancer

Cited by 14 publications

References 29 publications

BRCA Mutations and MicroRNA Expression Patterns in the Peripheral Blood of Breast Cancer Patients

BRCA Mutations and MicroRNA Expression Patterns in the Peripheral Blood of Breast Cancer Patients

The dysregulation of NME1, LINC00511, and LINC01028 could disturb the regular apoptosis process and promote breast cancer in the Isfahan population: integrated bioinformatics and experimental analyses

ADAMTS5 modulates breast cancer development as a diagnostic biomarker and potential tumor suppressor, regulating by BAIAP2-AS1, VTI1B, CRNDE, and hsa-miR-135b-3p: integrated systems biology and experimental approach

Contact Info

Product

Resources

About